22:02 , Dec 7, 2018 |  BC Extra  |  Financial News

WuXi AppTec prices Hong Kong offering in stormy market

Despite global trade headwinds and a choppy market for biopharma stocks in China, WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) managed to price its Hong Kong listing within its proposed range Friday, potentially raising HK$7.9 billion...
19:07 , Dec 7, 2018 |  BC Week In Review  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
23:31 , Dec 6, 2018 |  BC Extra  |  Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
21:58 , Sep 21, 2018 |  BioCentury  |  Finance

Funding WuXi’s expansion

WuXi AppTec Co. Ltd. (Shanghai:603259) is showing no signs of slowing down. The company is the largest R&D services platform in Asia, and a planned dual listing in Hong Kong that could bring in as...
03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:28 , Jul 11, 2018 |  BC Extra  |  Company News

Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
17:52 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Chinese investors lead Grail's $300M series C

Cancer detection company Grail Inc. (Menlo Park, Calif.) raised $300 million in an oversubscribed series C round on May 21. Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital led the round, with participation from...
17:40 , May 25, 2018 |  BioCentury  |  Finance

Grail’s Asia incentives

In light of Grail Inc.’s $300 million series C round from Chinese investors, the cancer detection company has several reasons to pursue a Hong Kong listing that go beyond high valuations. The series C round,...